Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History

Researchers employed mitochondrial single-cell assay for transposase-accessible chromatin with sequencing to profile 163,279 cells from nine patients with chronic lymphocytic leukemia collected across disease course and utilized mitochondrial DNA mutations as natural genetic markers of cancer clones.
[Cancer Discovery]
Abstract
Bookmark

No account yet? Register

0
Share

Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression

Investigators discovered that FLT3-ITD, one of the most frequent mutations in acute myeloid leukemia, was S-palmitoylated by the ZDHHC6 palmitoyl acyltransferase. Disruption of palmitoylation redirected FLT3-ITD to the plasma membrane and rewired its downstream signaling by activating AKT and ERK pathways in addition to STAT5.
[Blood]
Abstract
Bookmark

No account yet? Register

0
Share

Non-Conditioned Bone Marrow Chimeric Mouse Generation Using Culture-Based Enrichment of Hematopoietic Stem and Progenitor Cells

The authors described their development of cell culture techniques for the enrichment of functional hematopoietic stem and progenitor cells from mouse bone marrow without the use of fluorescence-activated cell sorting purification.
[Nature Communications]
Full ArticlePress Release
Bookmark

No account yet? Register

0
Share

Metabolic Alterations Mediated by STAT3 Promotes Drug Persistence in CML

By exploring the role of STAT3 in altering metabolism, researchers provided insight into identifying potential therapeutic targets for eliminating tyrosine kinase inhibitor-persistent leukemic stem cells.
[Leukemia]
Full Article
Bookmark

No account yet? Register

0
Share

IMiDs Uniquely Synergize with TKIs to Upregulate Apoptosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Cells Expressing a Dominant-Negative IKZF1 Isoform

Scientists found that lenalidomide, a representative of immunomodulatory drugs (IMiDs), specifically induced accumulation of Ik6 with the disappearance of functional isoforms within 24 hours in Ik6-positive Philadelphia chromosome-positive acute lymphoblastic leukemia cells in a neddylation-dependent manner.
[Cell Death Discovery]
Full Article
Bookmark

No account yet? Register

0
Share

Cryopreservation of Unrelated Donor Hematopoietic Stem Cells: The Right Answer for Transplantations during the COVID-19 Pandemic?

Investigators compared 32 patients who underwent unrelated donor (UD) hematopoietic stem cell transplantation (HSCT) using cryopreserved peripheral blood stem cells (PBSC) during the COVID-19 pandemic with 32 patients who underwent UD HSCT using fresh PBSC in the previous period.
[Bone Marrow Transplantation]
Full Article
Bookmark

No account yet? Register

0
Share

PRC2 Loss of Function Confers a Targetable Vulnerability to BET Proteins in T-ALL

The authors analyzed Polycomb Repressor Complex 2 (PRC2) alterations in a large series of 218 adult T-cell acute lymphoblastic leukemia (T-ALL) patients and found that PRC2 genetic lesions were frequent events in T-ALL and were not restricted to ETP-ALL.
[Blood]
Abstract
Bookmark

No account yet? Register

0
Share

60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy

The authors review the historical basis underpinning the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as advances in knowledge obtained by defining mechanisms of allo-HSCT activity.
[Cancer Research]
Abstract
Bookmark

No account yet? Register

0
Share

Inhibition of Translation Initiation Factor eIF4a Inactivates Heat Shock Factor 1 (HSF1) and Exerts Anti-Leukemia Activity in AML

Investigators provide a novel therapeutic rationale for co-targeting eukaryotic initiation factor 4A (eIF4A) and FLT3 to address the clinical challenge of treating FLT3-mutant acute myeloid leukemia.
[Leukemia]
Abstract
Bookmark

No account yet? Register

0
Share

Bristol Myers Squibb Announces Positive Topline Results from Phase III TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma

Bristol Myers Squibb announced positive results from TRANSFORM, a Phase III study evaluating Breyanzi as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma compared to salvage therapy followed by high-dose chemotherapy and hematopoietic stem cell transplant.
[Bristol Myers Squibb]
Press Release
Bookmark

No account yet? Register

0
Share

GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease

Global Blood Therapeutics, Inc. has awarded approximately $450,000 to US community-based organizations and institutions as part of the company’s 2021 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program. The program provides support to accelerate the development of sustainable access-to-care programs for people living with sickle cell disease.
[Global Blood Therapeutic, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share
Share